Prime Medicine, Inc. (PRME) Price & Analysis

Compare

691 Followers

PRME Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.11 - $6.75

Previous CloseN/A

Volume144.88K

Average Volume (3M)3.71M

Market Cap

$596.08M

Enterprise Value$1.65B

Total Cash (Recent Filing)$144.26M

Total Debt (Recent Filing)$121.15M

Price to Earnings (P/E)―

Beta3.32

Next Earnings

Aug 06, 2025

EPS Estimate

-0.36

Last Dividend Ex-Date

Sep 10, 2019

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.40

Shares Outstanding131,294,450

10 Day Avg. Volume5,540,893

30 Day Avg. Volume3,705,170

Financial Highlights & Ratios

PEG Ratio0.29

Price to Book (P/B)-6.15

Price to Sales (P/S)0.00

P/FCF Ratio-12.21

Enterprise Value/Market Cap2.76

Enterprise Value/Revenue10.34

Enterprise Value/Gross Profit41.28

Enterprise Value/Ebitda-2.04

Forecast

1Y Price Target

$5.38

Price Target Upside18.50% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering8

Prime Medicine, Inc. News

See All PRME News

See All News >

Bulls Say, Bears Say

Bulls Say

Acquisition PotentialPrime Medicine is seen as a prime candidate for acquisition due to its relatively attractive valuation.

Business Development OpportunitiesPrime intends to leverage the sizable amount of preclinical data generated across multiple indications and their expertise across a range of prime editing capabilities for potential BD deals, which could bolster the company with non-dilutive capital.

Technology AdvantagePrime's prime editing technology does not suffer from bystander edits and can perform all 12 possible base-to-base conversions without a DNA template.

Bears Say

Cash Flow ConcernsThe company's cash runway supports operations only into 1H26 after implementing cost-cutting measures, which is well short of management’s guidance of initial in-vivo clinical data for Wilson’s and AATD in 2027.

Clinical Data DependencyIt is unlikely that an acquisition will happen without clinical data from their Wilson Disease or AATD programs.

Revenue Model ImpactThe decision to remove revenues from deprioritized programs and only model revenue contribution from Wilson’s Disease and AATD has led to a restructuring of the PRME model, affecting the target price.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

34.70% Insiders

6.99% Mutual Funds

28.80% Other Institutional Investors

22.50% Public Companies and Individual Investors

Detailed Ownership Overview >

PRME FAQ

What was Prime Medicine, Inc.’s price range in the past 12 months?

Prime Medicine, Inc. lowest stock price was $1.11 and its highest was $6.75 in the past 12 months.

What is Prime Medicine, Inc.’s market cap?

Prime Medicine, Inc.’s market cap is $596.08M.

When is Prime Medicine, Inc.’s upcoming earnings report date?

Prime Medicine, Inc.’s upcoming earnings report date is Aug 06, 2025 which is in 25 days.

How were Prime Medicine, Inc.’s earnings last quarter?

Prime Medicine, Inc. released its earnings results on May 08, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.313 by -$0.087.

Is Prime Medicine, Inc. overvalued?

According to Wall Street analysts Prime Medicine, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Prime Medicine, Inc. pay dividends?

Prime Medicine, Inc. pays a Quarterly dividend of $0.8 which represents an annual dividend yield of N/A. See more information on Prime Medicine, Inc. dividends here

What is Prime Medicine, Inc.’s EPS estimate?

Prime Medicine, Inc.’s EPS estimate is -0.36.

How many shares outstanding does Prime Medicine, Inc. have?

Prime Medicine, Inc. has 131,294,450 shares outstanding.

What happened to Prime Medicine, Inc.’s price movement after its last earnings report?

Prime Medicine, Inc. reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.313. Following the earnings report the stock price went down -7.042%.

Which hedge fund is a major shareholder of Prime Medicine, Inc.?

Currently, no hedge funds are holding shares in PRME

Prime Medicine, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-115.21%

Trailing 12-Months

Asset Growth

5.39%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Prime Medicine, Inc.

Prime Medicine, Inc. (PRME) is a biotechnology company focusing on developing and delivering innovative gene-editing therapies. The company operates in the healthcare sector, specifically within the field of genomics and precision medicine. Prime Medicine aims to leverage its proprietary technology platforms to address a wide range of genetic disorders by precisely correcting disease-causing mutations at their source.

PRME Stock 12 Month Forecast

Average Price Target

$5.38

▲(18.50%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","5":"$5","10":"$10","2.5":"$2.5","7.5":"$7.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.5,5,7.5,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.73,3.212307692307692,3.6946153846153846,4.176923076923076,4.659230769230769,5.141538461538461,5.623846153846154,6.1061538461538465,6.588461538461538,7.07076923076923,7.553076923076922,8.035384615384615,8.517692307692307,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.73,2.933846153846154,3.1376923076923076,3.3415384615384616,3.5453846153846156,3.749230769230769,3.953076923076923,4.156923076923077,4.360769230769231,4.564615384615385,4.768461538461539,4.972307692307693,5.176153846153847,{"y":5.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.73,2.6353846153846154,2.540769230769231,2.4461538461538463,2.3515384615384614,2.256923076923077,2.1623076923076923,2.0676923076923077,1.9730769230769232,1.8784615384615384,1.7838461538461539,1.6892307692307693,1.5946153846153845,{"y":1.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.76,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.27,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.19,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.28,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.45,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.03,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.45,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.92,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.52,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.73,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >